{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:42:58Z","timestamp":1792183378421,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["GWVI-11.2-XD18"],"award-info":[{"award-number":["GWVI-11.2-XD18"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23J41900200"],"award-info":[{"award-number":["23J41900200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571246"],"award-info":[{"award-number":["82571246"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82388101"],"award-info":[{"award-number":["82388101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471130"],"award-info":[{"award-number":["82471130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xcrm.2026.102869","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:00:53Z","timestamp":1781276453000},"page":"102869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Subretinal rAAV2-based VEGF-Trap gene therapy for neovascular age-related macular degeneration: Preclinical assessment and phase 1 trial results"],"prefix":"10.1016","volume":"7","author":[{"given":"Tong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqiong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosa","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyu","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minlu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peirong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junran","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5015-0945","authenticated-orcid":false,"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102869_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-Related Macular Degeneration: A Review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2026.102869_bib2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102869_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xcrm.2026.102869_bib5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","article-title":"Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration","volume":"157","author":"Holekamp","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.xcrm.2026.102869_bib6","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","article-title":"Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents","volume":"138","author":"Evans","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.xcrm.2026.102869_bib7","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2214-109X(20)30425-3","article-title":"Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study","volume":"9","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.xcrm.2026.102869_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41433-021-01842-1","article-title":"Review of gene therapies for age-related macular degeneration","volume":"36","author":"Khanani","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xcrm.2026.102869_bib9","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial","volume":"386","author":"Rakoczy","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102869_bib10","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102869_bib11","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102869_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates","volume":"16","author":"Yiu","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.102869_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/iovs.64.7.39","article-title":"Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions","volume":"64","author":"Drag","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.xcrm.2026.102869_bib14","author":"Pitcher"},{"key":"10.1016\/j.xcrm.2026.102869_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.xcrm.2026.102869_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102869_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.xcrm.2026.102869_bib18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF Trap","volume":"92","author":"Stewart","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.xcrm.2026.102869_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100844","article-title":"Cell types and cell circuits in human and non-human primate retina","volume":"78","author":"Gr\u00fcnert","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.xcrm.2026.102869_bib20","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1073\/pnas.0611492104","article-title":"Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies","volume":"104","author":"Gerber","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102869_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1089\/hgtb.2012.197","article-title":"Induction of aberrant vascular growth, but not of normal angiogenesis, by cell-based expression of different doses of human and mouse VEGF is species-dependent","volume":"24","author":"Mujagic","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.xcrm.2026.102869_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00417-008-0936-y","article-title":"Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?","volume":"247","author":"Lu","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.xcrm.2026.102869_bib23","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1167\/iovs.07-1175","article-title":"Interaction between bevacizumab and murine VEGF-A: a reassessment","volume":"49","author":"Yu","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.xcrm.2026.102869_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.xcrm.2026.102869_bib26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","article-title":"Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration","volume":"27","author":"Grishanin","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102869_bib27","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1167\/iovs.15-17279","article-title":"Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes","volume":"56","author":"Niwa","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.xcrm.2026.102869_bib28","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1167\/iovs.15-16418","article-title":"Intraocular Pharmacokinetics of Aflibercept and Vascular Endothelial Growth Factor-A","volume":"56","author":"Celik","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.xcrm.2026.102869_bib29","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","volume":"38","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102869_bib30","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1089\/hum.2018.144","article-title":"Dosage Thresholds and Influence of Transgene Cassette in Adeno-Associated Virus-Related Toxicity","volume":"29","author":"Khabou","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102869_bib31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jcp.21224","article-title":"DNA methylation: the nuts and bolts of repression","volume":"213","author":"Miranda","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.xcrm.2026.102869_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tibs.2005.12.008","article-title":"Genomic DNA methylation: the mark and its mediators","volume":"31","author":"Klose","year":"2006","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.xcrm.2026.102869_bib33","article-title":"The presence of CpGs in AAV gene therapy vectors induces a plasmacytoid dendritic cell-like population very early after administration","volume":"399\u2013400","author":"Glenn","year":"2024","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.xcrm.2026.102869_bib34","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102869_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/hum.2019.144","article-title":"Ocular Inflammatory Response to Intravitreal Injection of Adeno-Associated Virus Vector: Relative Contribution of Genome and Capsid","volume":"31","author":"Timmers","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102869_bib36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","article-title":"Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice","volume":"128","author":"Maloney","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xcrm.2026.102869_bib37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40123-025-01098-y","article-title":"Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis","volume":"14","author":"Wojciechowski","year":"2025","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.xcrm.2026.102869_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/gt.2014.115","article-title":"Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates","volume":"22","author":"Kotterman","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102869_bib39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis","volume":"6","author":"Gange","year":"2022","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.xcrm.2026.102869_bib40","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41434-021-00294-2","article-title":"Injection pressure levels for creating blebs during subretinal gene therapy","volume":"29","author":"Scruggs","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102869_bib41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ophtha.2016.07.033","article-title":"Associations with Retinal Pigment Epithelium Thickness Measures in a Large Cohort: Results from the UK Biobank","volume":"124","author":"Ko","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xcrm.2026.102869_bib42","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1167\/iovs.13-12445","article-title":"Quantitative fundus autofluorescence in healthy eyes","volume":"54","author":"Greenberg","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.xcrm.2026.102869_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2025.100144","article-title":"Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS)","volume":"14","author":"Ruamviboonsuk","year":"2025","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"10.1016\/j.xcrm.2026.102869_bib44","first-page":"322","article-title":"Pain management standards in the eighth edition of the Guide for the Care and Use of Laboratory Animals","volume":"51","author":"Carbone","year":"2012","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"10.1016\/j.xcrm.2026.102869_bib45","series-title":"International Ethical Guidelines for Health-Related Research Involving Humans","year":"2016"},{"key":"10.1016\/j.xcrm.2026.102869_bib46","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41596-022-00689-4","article-title":"Subretinal injection in mice to study retinal physiology and disease","volume":"17","author":"Huang","year":"2022","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.102869_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2177","article-title":"Targeting C3b\/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102869_bib48","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nprot.2017.032","article-title":"Comprehensive analysis of mouse retinal mononuclear phagocytes","volume":"12","author":"L\u00fcckoff","year":"2017","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.102869_bib49","first-page":"887","article-title":"Expert consensus on surgical technique for subretinal injection of gene therapy in China","volume":"40","year":"2022","journal-title":"Chin. J. Exp. Ophthalmol."},{"key":"10.1016\/j.xcrm.2026.102869_bib50","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/IAE.0000000000002609","article-title":"Surgical Technique for Subretinal Gene Therapy in Humans with Inherited Retinal Degeneration","volume":"39","author":"Davis","year":"2019","journal-title":"Retina"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:05:48Z","timestamp":1784750748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126002867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666379126002867"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102869","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subretinal rAAV2-based VEGF-Trap gene therapy for neovascular age-related macular degeneration: Preclinical assessment and phase 1 trial results","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102869"}}